LLY catalysts
Catalysts and events linked to LLY, newest first.
LLY stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Viking raises $575 million to fund obesity trials through 2028 2026-10-19 · Mixed | obesity-drug competition and category valuation | The source frames Viking within the obesity-drug competitive set that includes Eli Lilly. | Not recorded |
| Viking financing keeps obesity trial runway open through 2028 2026-10-19 · Mixed | obesity category competition from a better-funded challenger | VKTX's runway affects competitive optionality in obesity drugs. | Not recorded |
| Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity Trials 2026-10-19 · Watch | competitive threat assessment in metabolic therapeutics pipeline | VK2735 Phase 3 funding secures long-term competition in the GLP-1/GIP category. | Not recorded |
| Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli Lilly 2026-10-19 · Up | institutional defensives rebalancing | Citadel increased holding by 291% in Q2 | Not recorded |
| Viking raises $575 million to fund obesity pipeline trials 2026-10-19 · Mixed | obesity pipeline competition and capital intensity in the GLP-1 space | LLY is named as a related ticker in the source. | Not recorded |
| Viking raises $575 million to fund obesity phase 3 trials 2026-10-19 · Mixed | more funded obesity competition can affect future market-share and multiple assumptions | The source says Viking will fund multiple phase 3 trials for its obesity drug. | Not recorded |
| Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 Trials 2026-10-19 · Watch | competitive pipeline threat in commercial obesity therapeutics | Viking's VK2735 directly competes with Eli Lilly's incretin portfolio. | Not recorded |
| Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity Trials 2026-10-19 · Watch | obesity drug competitive pipeline landscape | Eli Lilly holds significant commercial market share in the GLP-1 space. | Not recorded |
Do these developments change your position?
Review LLY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Viking raises $575 million to fund obesity phase 3 trialsLLY NVO VKTX
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
- 2026-10-12GLP-1 Penetration Reaches 11% of US Adults, Pressuring Packaged Snack and Beverage VolumesLLY PEP+0.49%
- 2026-10-12GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food SpendLLY MDLZ PEP+0.49%
- 2026-10-12GLP-1 Penetration Reaches 11% of US Adults, Pressuring Packaged Snack and Beverage VolumesLLY PEP+0.49%
- 2026-10-12GLP-1 usage reaches 11% of US adults, shifting grocery and snack spendLLY MDLZ NVO PEP+0.49%
- 2026-10-12GLP-1 Penetration Reaches 11% of US Adults, Pressuring Packaged Snack and Beverage VolumesLLY PEP+0.49%
- 2026-10-12GLP-1 usage reaches 11% of US adults, shifting grocery and snack spendLLY MDLZ NVO PEP+0.49%
- 2026-10-12GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food SpendLLY MDLZ PEP+0.49%
- 2026-10-11Viking Therapeutics Advances Oral Obesity Candidate VK2735 Into Phase 3 TrialsLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical TestingLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Drug VK2735 to Phase 3 TrialsLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Drug VK2735 to Phase 3 Clinical TrialsLLY VKTX
- 2026-10-09Novo Nordisk Draws Valuation Trap Label as GLP-1 Competition IntensifiesLLY NVO
- 2026-10-09Novo Nordisk Draws Valuation Trap Label as GLP-1 Competition IntensifiesLLY NVO
- 2026-10-07Energy Price Pressures and Inflation Risks Prompt Rotation Into Defensive Healthcare NamesLLY MDT
- 2026-10-07Energy Price Pressures and Inflation Risks Prompt Rotation Into Defensive Healthcare NamesLLY MDT
- 2026-10-07Energy Price Pressures and Inflation Risks Prompt Rotation Into Defensive Healthcare NamesLLY MDT
- 2026-09-30Novo Nordisk Warns of Revenue Growth Deceleration on Patent ExpiryLLY
- 2026-09-30Novo Nordisk Warns of Revenue Growth Deceleration on Patent ExpiryLLY NVO-1.35%
- 2026-09-30Novo Nordisk Cites Slowing Growth on Ozempic Patent Cliff ConcernsLLY NVO-1.35%
- 2026-09-30Viking Reports 16% to 19% Weight Loss in VK2735 Obesity Clinical TrialLLY VKTX
- 2026-09-30Novo Nordisk Warns of Revenue Growth Deceleration on Patent ExpiryLLY NVO-1.35%
- 2026-09-30Viking Therapeutics Reports 16% to 19% Weight Loss for VK2735LLY VKTX
- 2026-09-30Novo Nordisk Warns on Growth Deceleration and Long-Term Ozempic Patent ExpiryLLY NVO-1.35%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataLLY
- 2026-09-28Eli Lilly Discontinues New GLP-1 Weight-Loss Candidate on EfficacyLLY NVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Due to Subpar EfficacyLLY NVO-3.02%
- 2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise leadLLY NVO-3.02%
- 2026-09-28Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy ReviewLLY NVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataLLY NVO-3.02%
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueLLY NVO-3.81%
- 2026-09-27Eli Lilly discontinues developmental obesity drug over unmet efficacy thresholdLLY NVO-3.81%
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of RevenueLLY NVO-3.81%
- 2026-09-27Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy StandardsLLY NVO-3.81%
- 2026-09-27Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% RevenueLLY NVO-3.81%
- 2026-09-24InnoCare and Eli Lilly enter multi-target discovery pact worth up to $3.35 billionLLY
- 2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal Worth Up to $3.35BLLY
- 2026-09-24Eli Lilly Signs Up to $3.35B Drug Discovery Deal With InnoCareLLY
- 2026-09-24Eli Lilly Signs Up to $3.35B Drug Discovery Deal With InnoCareLLY
- 2026-09-24Eli Lilly and InnoCare Enter Collaboration Agreement Valued Up to $3.35BLLY
- 2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal Worth Up to $3.35BLLY
- 2026-09-24InnoCare and Eli Lilly Enter Strategic Licensing Deal with Up to $3.35B in MilestonesLLY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.